Eli Lilly
-
healthEli Lilly Partners with Insilico Medicine in $2.75B AI Drug Discovery Deal
Eli Lilly and Insilico Medicine have sealed a $2.75 billion partnership to accelerate AI-driven development of novel therapeutics for high-unmet medical needs.
-
healthEli Lilly Partners with Insilico for AI Drug Discovery
Lilly and Insilico extend collaboration for AI-driven drug development, with potential deal value up to $2.75 billion.
-
healthPrice Wars Reshape US Weight-Loss Drug Market
Eli Lilly and rivals slash prices amid fierce competition, pushing direct-to-consumer models while millions still lack insurance coverage.
-
techRoche Deploys 3,500 Nvidia Blackwell GPUs for Drug Discovery
Roche accelerates pharmaceutical R&D with 3,500 Nvidia Blackwell GPUs, targeting obesity drugs and challenging Eli Lilly's market dominance.
-
healthNew GLP-1 Pill Outperforms Oral Semaglutide in Diabetes Trial
A new daily oral GLP-1 pill, orforglipron, shows superior blood glucose control compared to oral semaglutide in Type 2 diabetes patients, according to a Phase III trial.
-
healthEli Lilly's Orforglipron Shows Promise in Weight Loss Drug Race
New clinical trial results suggest Eli Lilly's orforglipron may outperform oral semaglutide in glycemic control and weight reduction for type 2 diabetes.
-
healthEli Lilly's Orforglipron Pill Shows Superior Weight Loss in Trials
New oral weight-loss drug orforglipron demonstrates significant efficacy in clinical trials, outperforming existing oral semaglutide treatments.
-
healthNovo Nordisk Slashes Ozempic & Wegovy Prices Amid Fierce Competition
Novo Nordisk announces significant list price reductions for Ozempic and Wegovy, aiming to boost affordability for insured patients amidst rising competition and market pressures.